TAT-OSBP-1-MKK6(E), a novel TAT-fusion protein with high selectivity for human ovarian cancer, exhibits anti-tumor activity

Medical Oncology
Jiali ZhongJin Yuan

Abstract

To improve the selectivity of TAT-fusion proteins for targeted cancer therapy, we developed a novel TAT-based target-specific fusion protein, TAT-OSBP-1-MKK6(E), and evaluated its selectivity and anti-tumor activity in vitro and in vivo. The fusion protein containing TAT-OSBP-1-MKK6(E) has three functional domains: (1) the protein transduction domain of TAT, (2) the human ovarian cancer HO8910 cell-specific binding peptide (OSBP-1) and (3) the potential anti-tumor effector domain of MKK6(E). The transduction efficiency, selectivity, cytotoxicity and apoptotic effect of TAT-OSBP-1-MKK6(E) were examined using immunofluorescence, CCK8 assay and flow cytometry. The in vivo anti-tumor efficacy and target specificity of the fusion protein were evaluated using a nude mouse model with subcutaneous xenografts of human ovarian cancer HO8910 cells. Tumor-bearing mice were divided into three treatment groups that received tail vein injections of TAT-OSBP-1-MKK6(E), TAT-OSBP-1 or normal saline. Tumor growth inhibition was determined by tumor volume, weight and morphology. The distribution and apoptotic effect of TAT-OSBP-1-MKK6(E) were assessed by immunohistochemical staining and TUNEL assays. TAT-OSBP-1-MKK6(E) can be selectively internali...Continue Reading

References

Mar 22, 2007·Journal of Cellular Physiology·Ju-Pi Li, Jia-Ling Yang
Apr 9, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yongjun LiuChen Lin
Feb 11, 2010·Molecular Cancer Research : MCR·Bing DuMin Qian
Apr 21, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yamini ArthanariConstantinos Demonacos
Jun 24, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xilin SunXiaoyuan Chen
Aug 16, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Prisca BoisguerinBernard Lebleu
Mar 17, 2012·Journal of the American Chemical Society·Limin PanJianlin Shi
Apr 17, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Jun-Jiang WangXue-Qing Yao
May 9, 2012·World Journal of Gastroenterology : WJG·Wen-Jie ZhangShao-Ying Lu
Sep 4, 2012·Neuroscience Letters·Rongjie YuJiansu Chen
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Oct 3, 2013·Neuromolecular Medicine·Muneesa BashirFirdous A Khanday
Dec 3, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Feihu WangFang Jin
Jul 12, 2014·Medical Oncology·Babak BakhshinejadMajid Sadeghizadeh
Jul 24, 2014·Apoptosis : an International Journal on Programmed Cell Death·Kwon JeongWonchae Choe

❮ Previous
Next ❯

Citations

Oct 27, 2017·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Eden R PadayacheeStefan Barth

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis